Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.

Yang F, Zhou L, Zhang J, Wang Q, Cai Q, Wang J, Wu C, Li X, Zhang J, Zheng Y, Ma X, Zhu H, Shi Z

International journal of surgery (London, England)8 Aug 2025Cited by 1 (Europe PMC)

PMID40788007PMCIDPMC12695207DOI10.1097/js9.0000000000003156PepBankPUB-40788007

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-SA. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In 30 adults with chronic plantar heel pain given semaglutide, mean FHSQ pain scores improved from 28.09 to 60.28 (P < 0.001).
In plain wordsIn 30 adults with long-lasting heel pain given semaglutide, pain scores improved over 12 months. There was no control group.
Peptide
Semaglutide
Outcome
IncreaseFHSQ pain score before and after semaglutide (pilot)
Study
n = 30
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
FHSQ pain score
28.09 points
baseline
FHSQ pain score
60.28 points
follow-up
Source sentences
Summary
In the interventional substudy, mean FHSQ pain scores improved from 28.09 ± 10.34 at baseline to 60.28 ± 21.34 at follow-up ( P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
As supporting evidence, a pilot interventional study was conducted in 30 patients with chronic PHP who received semaglutide, with outcomes assessed over 12 months using before-and-after evaluations of pain, function, and imaging.
Report a problemFND-4078800708
02HumanNon-randomized trialEfficacy outcome
In 30 adults with chronic plantar heel pain given semaglutide, FHSQ function scores increased from 27.23 to 80.71 (P < 0.001).
In plain wordsIn 30 adults with long-lasting heel pain given semaglutide, foot function scores rose over 12 months. There was no control group.
Peptide
Semaglutide
Outcome
IncreaseFHSQ function score before and after semaglutide (pilot)
Study
n = 30
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
FHSQ function score
27.23 points
baseline
FHSQ function score
80.71 points
follow-up
Source sentences
Summary
FHSQ function subdomain scores increased from 27.23 ± 17.44 to 80.71 ± 19.55 ( P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
As supporting evidence, a pilot interventional study was conducted in 30 patients with chronic PHP who received semaglutide, with outcomes assessed over 12 months using before-and-after evaluations of pain, function, and imaging.
Report a problemFND-4078800709
03HumanNon-randomized trialEfficacy outcome
In the pilot study of 30 adults, first-step pain improved with semaglutide (P < 0.001).
In plain wordsIn 30 adults with long-lasting heel pain given semaglutide, first-step pain improved over 12 months. There was no control group.
Peptide
Semaglutide
Outcome
DecreaseFirst-step pain before and after semaglutide (pilot)
Study
n = 30
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
For interventional use of semaglutide, improvements in all measured outcomes (FHSQ pain/function subscales, first-step pain and thickness of plantar fascia) were observed with all P values less than 0.001.
1 context sentence(design, population, supporting numbers)
Summary · context
As supporting evidence, a pilot interventional study was conducted in 30 patients with chronic PHP who received semaglutide, with outcomes assessed over 12 months using before-and-after evaluations of pain, function, and imaging.
Report a problemFND-4078800710
04HumanNon-randomized trialEfficacy outcome
In the pilot study of 30 adults, plantar fascia thickness improved with semaglutide (P < 0.001).
In plain wordsIn 30 adults with long-lasting heel pain given semaglutide, scans showed an improvement in foot tissue thickness. There was no control group.
Peptide
Semaglutide
Outcome
DecreasePlantar fascia thickness before and after semaglutide (pilot)
Study
n = 30
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
For interventional use of semaglutide, improvements in all measured outcomes (FHSQ pain/function subscales, first-step pain and thickness of plantar fascia) were observed with all P values less than 0.001.
1 context sentence(design, population, supporting numbers)
Summary · context
As supporting evidence, a pilot interventional study was conducted in 30 patients with chronic PHP who received semaglutide, with outcomes assessed over 12 months using before-and-after evaluations of pain, function, and imaging.
Report a problemFND-4078800711
05HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, the change in FHSQ pain subdomain from baseline was higher in semaglutide users than in controls (adjusted mean difference 14.86, 95% CI 9.97 to 19.75, P < 0.001).
In plain wordsIn adults with long-lasting heel pain, semaglutide users had a larger improvement in pain score than people who did not take it.
Peptide
Semaglutide
Outcome
IncreaseChange in FHSQ pain subdomain
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Primary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Measurements
Adjusted mean difference in FHSQ pain change
14.86 points
semaglutide vs control
Source sentences
Summary
Change from baseline in FHSQ pain subdomain was significantly higher in semaglutide group compared with control group (adjusted mean difference, 14.86 [95% CI, 9.97 to 19.75], P < 0.001), favoring semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800701
06HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, the FHSQ function subdomain showed results similar to pain, favoring semaglutide users over controls.
In plain wordsIn adults with long-lasting heel pain, semaglutide users also did better than people who did not take it on a foot function score.
Peptide
Semaglutide
Outcome
IncreaseChange in FHSQ function subdomain
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Source sentences
Summary
Similar results were observed from the analysis of FHSQ function subdomain, first-step pain and several therapeutic interventions (oral and topical NSAIDs, corticosteroid injection and orthosis wearing).
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800702
07HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, first-step pain showed similar results, favoring semaglutide users over controls.
In plain wordsIn adults with long-lasting heel pain, semaglutide users had less first-step pain than people who did not take it.
Peptide
Semaglutide
Outcome
DecreaseFirst-step pain
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Source sentences
Summary
Similar results were observed from the analysis of FHSQ function subdomain, first-step pain
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800703
08HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, semaglutide users needed fewer oral and topical NSAIDs than controls, in a result described as similar to pain.
In plain wordsIn adults with long-lasting heel pain, semaglutide users used fewer anti-inflammatory painkillers than people who did not take it.
Peptide
Semaglutide
Outcome
DecreaseUse of oral and topical NSAIDs
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Source sentences
Summary
Similar results were observed from the analysis of FHSQ function subdomain, first-step pain and several therapeutic interventions (oral and topical NSAIDs
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800704
09HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, semaglutide users needed fewer corticosteroid injections than controls, in a result described as similar to pain.
In plain wordsIn adults with long-lasting heel pain, semaglutide users had fewer steroid injections than people who did not take it.
Peptide
Semaglutide
Outcome
DecreaseUse of corticosteroid injection
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Source sentences
Summary
several therapeutic interventions (oral and topical NSAIDs, corticosteroid injection
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800705
10HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, semaglutide users needed orthosis wearing less than controls, in a result described as similar to pain.
In plain wordsIn adults with long-lasting heel pain, semaglutide users needed foot supports less than people who did not take it.
Peptide
Semaglutide
Outcome
DecreaseOrthosis wearing
Study
n = 2,902
Comparator
Control group (no semaglutide)
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Source sentences
Summary
several therapeutic interventions (oral and topical NSAIDs, corticosteroid injection and orthosis wearing)
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800706
11HumanObservational studyEfficacy outcome
In adults with chronic plantar heel pain, plantar fascia thickening velocity was lower in semaglutide users than in controls (-0.25 mm/year, P = 0.002).
In plain wordsIn adults with long-lasting heel pain, the foot tissue thickened more slowly in semaglutide users than in people who did not take it.
Peptide
Semaglutide
Outcome
DecreasePlantar fascia thickening velocity
Study
n = 2,902
Comparator
Control group (no semaglutide)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · at least 2 yearsAs given in this study (human).
Measurements
Plantar fascia thickening velocity difference
−0.25 mm/year
semaglutide vs control
Source sentences
Summary
For structural alterations, plantar fascia thickening velocity was significantly lower in the semaglutide group when compared with control group (-0.25 mm/year [-0.41 to -0.09], P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In the prospective observational cohort, 92 out of 2902 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss in the final analysis were identified.
Summary · context
In the observational arm, more than 3000 adults with chronic PHP (duration of symptoms >6 months) were recruited with at least 2-year follow-up from two medical centers.
Report a problemFND-4078800707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.

Summary

Results from this study11

Version history

Subjects

Publication types

MeSH terms

Keywords